Free Newsletter
Generics beat down drug price inflation
Generics may be the bane of Big Pharma, but they're inflation-fighting ninjas. Over the last 12 months, prescription drug prices edged up by a measly 1 percent--the lowest rate of inflation in three decades. Just two years ago, drug costs were rising at 4.4 percent annually.
The difference? More people are using generics, and generic versions of some of the most common, most popular drugs have come onto the market. And then there's the Wal-Mart effect: the $4 generics program Wal-Mart launched last fall, which quickly spread to competitors.
There's more rah-rah for generics to come, too. Several presidential candidates pin their plans for controlling healthcare costs onto the copycat drugs.
- read this article in The New York Times
Related Articles:
FDA backlog slows generic drug approval. Report
Dr. Reddy's make risky biogenerics move. Report
Generic battle looms for Lipitor. Report
Report claims generics could save system $20B. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: